Small molecule disease-modifying medicines
NRG is developing pipeline of brain-penetrant small molecule inhibitors of the mitochondrial permeability transition pore.
Source: drugtargetreview.com
Page 5 - Biomedical Catalyst News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Biomedical Catalyst. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Biomedical Catalyst Today - Breaking & Trending Today
Mitochondria in focus as 4BIO Capital co-leads financing in LUCA Science
4BIO Capital has co-led Series B financing in LUCA Science Inc., which is developing a novel class of mitochondria biopharmaceutical agents.
Source: labiotech.eu
NRG receives £2.68m funding boost for neurodegenerative disorders
NRG Therapeutics announces multi-million Innovate UK Award to develop treatments for Parkinson’s and motor neurone disease - News - PharmaTimes
Source: pharmatimes.com
NRG Therapeutics developing new Parkinson's and MND treatments
UK neuroscience company NRG Therapeutics Ltd has received an award to fund preclinical development of its novel small molecule disease-modifying medicines for the treatment of Parkinson's disease, motor neuron disease (MND) and other chronic neurodegenerative disorders.
Source: labiotech.eu
NRG Therapeutics Announces £2.68M Innovate UK Award to Develop New Medicines to Treat Parkinson's and Motor Neuron Disease
NRG Therapeutics Ltd (“NRG” or “company”), an innovative neuroscience company targeting mitochondrial dysfunction, is pleased to announce that it has received a highly competitive Biomedical Catalyst (BMC) award to fund pre-clinical development of its novel small molecule disease-modifying medicines for the treatment of Parkinson's disease, motor neuron disease (MND) and other debilitating chronic neurodegenerative disorders.
Source: biospace.com